Ally Bridge Group NY LLC Trims Stake in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Ally Bridge Group NY LLC has reduced its stake in Dianthus Therapeutics by 24.3%, now holding 80,584 shares, which comprises about 1.3% of its investment portfolio.
• Several analysts have given "outperform" ratings for Dianthus Therapeutics, with a consensus price target of $54.00, despite the company recently missing its earnings expectations.
• Dianthus Therapeutics is currently valued at a market cap of $767.73 million and reported a negative earnings per share of ($0.88) for the last quarter.

Ally Bridge Group NY LLC decreased its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 24.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 80,584 shares of the company's stock after selling 25,850 shares during the quarter. Dianthus Therapeutics accounts for approximately 1.3% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 22nd biggest holding. Ally Bridge Group NY LLC owned 0.25% of Dianthus Therapeutics worth $1,462,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. US Bancorp DE lifted its position in shares of Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after buying an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $59,000. GAMMA Investing LLC lifted its position in shares of Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after buying an additional 3,758 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Dianthus Therapeutics by 21.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company's stock worth $207,000 after buying an additional 1,647 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Dianthus Therapeutics by 38.7% during the 1st quarter. Invesco Ltd. now owns 15,978 shares of the company's stock worth $290,000 after buying an additional 4,457 shares in the last quarter. Institutional investors own 47.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on DNTH. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday. Wedbush raised their price target on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a research note on Thursday, August 21st. William Blair started coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an "outperform" rating for the company. Finally, Robert W. Baird decreased their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $54.00.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock traded up $4.23 during mid-day trading on Monday, reaching $30.73. The company's stock had a trading volume of 4,306,532 shares, compared to its average volume of 350,015. Dianthus Therapeutics, Inc. has a 12-month low of $13.36 and a 12-month high of $32.50. The company has a market capitalization of $989.04 million, a P/E ratio of -9.59 and a beta of 1.46. The firm's fifty day moving average price is $21.27 and its two-hundred day moving average price is $20.03.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The firm had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.